Global Nuclear Medicine Equipments Market Size By Type (Hybrid PET, Hybrid SPECT), By Application (Neurology, Oncology), By Region, And Segment Forecasts, 2023 to 2032

The Global Nuclear Medicine Equipment Market was valued at USD 3.4 billion in 2023 and is projected to surpass USD 6.1 billion by 2031, expanding at a CAGR of 7.6% during the forecast period of 2023–2031. This growth is attributed to increasing demand for early and accurate diagnostic solutions, the rising prevalence of cancer and cardiovascular diseases, and significant technological advancements in imaging modalities such as SPECT and PET systems. As healthcare systems shift towards more personalized and precision-based care, nuclear medicine equipment is becoming increasingly indispensable for diagnostic and therapeutic purposes across clinical settings.

Drivers:

1. Increasing Incidence of Chronic Diseases:

The rising prevalence of cancer, cardiovascular disorders, and neurological diseases has accelerated the demand for nuclear imaging for early and precise diagnosis. The ability of nuclear medicine equipment to detect disease at a molecular level is a key advantage.

2. Technological Advancements in Imaging Equipment:

Innovations such as hybrid imaging systems (e.g., PET/CT and SPECT/CT), improved spatial resolution, and integration with AI and software-based image enhancement are enhancing diagnostic accuracy and fueling market demand.

3. Growing Adoption of Personalized Medicine:

The shift towards individualized treatment approaches is driving the use of nuclear medicine for theranostics (therapy + diagnostics), which requires advanced imaging equipment for patient stratification and treatment monitoring.

Restraints:

1. High Capital and Operational Costs:

Nuclear medicine equipment involves significant upfront investment, maintenance costs, and compliance with stringent safety regulations, which can limit adoption in small and mid-sized healthcare facilities.

2. Regulatory and Supply Chain Challenges:

The market is also affected by short half-lives of radiotracers, strict handling regulations, and the complexity of establishing consistent isotope supply chains, especially in emerging regions.

Opportunity:

1. Rising Demand in Emerging Markets:

Countries in Asia-Pacific and Latin America are witnessing improvements in healthcare infrastructure and increased awareness about early diagnosis, offering untapped opportunities for market expansion.

2. Advancements in Radiotracers and AI Integration:

The development of novel radiopharmaceuticals and the integration of artificial intelligence for data interpretation and workflow automation are expected to redefine the clinical utility and efficiency of nuclear medicine imaging.

Market by System Type Insights:

Based on system type, Single-Photon Emission Computed Tomography (SPECT) equipment accounted for the largest market share in 2023. Its widespread use in cardiology and oncology diagnostics, along with lower costs compared to PET systems, supports its dominance. However, Positron Emission Tomography (PET) is projected to grow at the fastest rate due to its superior imaging resolution and rising use in neurology and personalized medicine.

Market by End-Use Insights:

Hospitals held the largest revenue share in 2023, driven by comprehensive diagnostic capabilities, advanced infrastructure, and growing patient inflow for chronic disease management. Diagnostic imaging centers are expected to witness robust growth during the forecast period owing to increased outsourcing of imaging services and demand for cost-effective diagnostics.

Market by Regional Insights:

North America dominated the market in 2023 due to the presence of a well-developed healthcare system, widespread adoption of advanced imaging modalities, and strong reimbursement structures. Meanwhile, Asia-Pacific is expected to exhibit the highest growth rate during the forecast period, supported by rising healthcare investments, expanding medical tourism, and a growing burden of non-communicable diseases.

Competitive Scenario:

Leading players in the Global Nuclear Medicine Equipment Market include GE Healthcare, Siemens Healthineers, Canon Medical Systems Corporation, Philips Healthcare, Digirad Corporation, Mediso Ltd., Neusoft Medical Systems, and Spectrum Dynamics Medical. These companies are actively investing in R&D, launching AI-integrated imaging systems, and forming strategic alliances to enhance their global footprint and product portfolios.

Scope of Work – Global Nuclear Medicine Equipment Market

Report Metric Details

Market Size (2023) USD 3.4 billion

Projected Market Size (2031) USD 6.1 billion

CAGR (2023–2031) 7.6%

Market Segments By System Type (SPECT, PET), By End-Use (Hospitals, Imaging Centers), By Region

Growth Drivers Rising chronic disease burden, Technological innovation, Personalized medicine integration

Opportunities Emerging market expansion, AI integration, Novel radiopharmaceutical development

Key Market Developments:

2023: Siemens Healthineers launched its AI-enabled Symbia Pro.specta SPECT/CT system, enhancing image quality and streamlining workflow.

2024: GE Healthcare announced a partnership with a leading oncology center to co-develop precision imaging systems tailored for theranostics.

2025: Philips Healthcare introduced its next-gen PET/MRI hybrid scanner with real-time AI diagnostics, expanding its portfolio in multi-modal imaging.

FAQs:

1) What is the current market size of the Global Nuclear Medicine Equipment Market?

The market was valued at USD 3.4